Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07856511) titled 'A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Jiankuan (Suzhou) Biotechnology Company Limited
Condition:
Rheumatoid Arthrits
Intervention:
Drug: Placebo
Drug: Proximod
Drug: Proximod
Drug: Placebo
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 15, 2026
Target Sample Size: 590
To know more, visit https://clinicaltr...